Abridge is an enterprise-grade AI platform that transforms clinical conversations into structured documentation and actionable insights. Founded by cardiologist Dr. Shiv Rao in 2018, the company uses generative AI and ambient listening to capture patient-clinician conversations and automatically generate clinical notes, reducing administrative burden and allowing clinicians to focus on patient care. The platform integrates with Epic EHR systems and supports 55 medical specialties across 28 languages, serving over 150 health systems including Kaiser Permanente, Mayo Clinic, Johns Hopkins, and UPMC.
SaaS📍 Pittsburgh, PennsylvaniaFounded 2018
Current Valuation
$5.7B
as of 2025-Q2
UNICORN
QL Price
$5.7B
+7% vs last round
QuantLogix's current estimate for Abridge, published 2026-10-07 — above the last disclosed round of $5.3B (2026-04).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$5.3B
2026-04
weight 0.7
Secondary market print
$6.1B
2026-06-27
weight 0.54
How this price has held up
No round has priced for Abridge since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-10-07 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Abridge, 2026-10-07 (0e9b3f25d6364aca).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Abridge going public?
No. Abridge is private and has not filed to go public. There is no S-1 on file.
What is Abridge's valuation in 2026?
Abridge is valued at $5.7B as of 2025-Q2, set by its Series E ($300M, Jun 2025). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Abridge filed an S-1?
No public S-1 is on file for Abridge.
Who are Abridge's investors?
Abridge's investors include Andreessen Horowitz, Lightspeed Venture Partners, Bessemer Venture Partners, Redpoint, Spark Capital, Kaiser Permanente Ventures and 7 more.
How much has Abridge raised?
Abridge has raised $1.0B in total, most recently a Series E of $300M in Jun 2025.
Is Abridge publicly traded — can you buy Abridge stock?
No. Abridge is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Abridge on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Shiv Rao
Founded
2018
HQ
Pittsburgh, Pennsylvania
Employees
488
Total Raised
$1.0B
Est. Revenue
$100M (2025-Q2)
Growth
900% YoY ARR growth; deployed to 150+ enterprise health systems; tracking 50M+ medical conversations annually
Last Round
Series E — $300M (Jun 2025)
IPO Status
Private
Fundraising Status
Series E · $300M · 1y 4mo ago
PrivateTotal raised $1.0B
Secondary Market
Implied price / share
$182.57
Last round price / share
$158.48
vs last round
+15.2%
Open interest
6
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series E
$300M
Jun 2025
—
—
Talent Signal
Hiring trend
▶ Hiring steady
-7% vs 2026-08
Open roles
42
via ashby
Product-build share
74%
engineering, research, product, design
Trajectory
strengthening
heavy product build — 74% of open roles are product-building functions (engineering/research/product) — 11 of 42 open roles are engineering.
Recent senior hire: 1 senior hire (CTO).
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Key Executive Moves
INSan OoCTO · 2026-09-09
From trusted-source news extraction (deep-enrich pipeline); dates approximate publication, not effective date.
Machine Learning Scientist (All Levels)Senior Platform EngineerSenior Full Stack Engineer, Integrations VistA Senior Application Security EngineerSenior Data ScientistMachine Learning Infrastructure Engineer, Model Inference
Counted from Abridge's live job board as of 2026-09-15; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Shiv RaoSandeep KonamFlorian Metze
Investors
Andreessen Horowitz · Lightspeed Venture Partners · Bessemer Venture Partners · Redpoint · Spark Capital · Kaiser Permanente Ventures · CVS Health Ventures · Khosla Ventures · California Health Care Foundation · NVIDIA NVentures · WndrCo · Emerson Collective · UPMC
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q2. Refreshed quarterly.